huIL5 Mouse
Product Name
huIL5 Mouse
Product ID
C001813
Strain Name
C57BL/6NCya-Il5tm1(hIL5)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “huIL5 Mouse (Catalog C001813) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
IL5
Gene Alias
EDF, TRF, IL-5
NCBI ID
Chromosome
Chr 5 (Human)
MGI ID
Datasheet
Strain Description
Interleukin-5 (IL-5) is a cytokine secreted by Th2 CD4+ T cells, mast cells, and type 2 innate lymphoid cells (ILC2s). It plays a pivotal role in regulating the proliferation, differentiation, activation, and survival of eosinophils [1]. The IL5 gene is located within the 5q31 region of human chromosome 5, clustered alongside other Th2 cytokine genes such as IL4 and IL13, and is co-regulated by transcription factors including GATA3 [2]. By binding to the IL-5 receptor alpha chain (IL-5Rα), IL-5 activates signaling pathways like JAK2-STAT5, thereby modulating eosinophil-associated immune responses [1-2]. Aberrant IL-5 expression is closely linked to various eosinophil-related disorders, including asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), hypereosinophilic syndrome, and allergic rhinitis, making the IL-5/IL-5Rα axis a prominent therapeutic target. Consequently, several antibody drugs targeting IL-5 or IL-5Rα, such as Mepolizumab and Benralizumab, have been approved or are currently under clinical investigation [3-4].
The huIL5 mouse is a humanized model generated by replacing the mouse Il5 gene sequence (from the start codon to the stop codon) with the corresponding human IL5 sequence via in situ substitution. This model is highly valuable for studying eosinophilic diseases (e.g., asthma, CRSwNP, and hypereosinophilic syndrome), allergic inflammatory immune regulation, and Th2 immune responses. Furthermore, it serves as a robust platform for the development of IL-5-targeted therapeutics.
Reference
Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(8):463-485.
Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy. 2010;40(4):563-575.
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM). Lancet. 2012;380(9842):651-659.
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma. Lancet. 2016;388(10056):2128-2141.
Strain Strategy
The sequences from the start codon to the stop codon of the endogenous mouse Il5 gene were replaced with the sequences from the start codon to the stop codon of the human IL5 gene.
Figure 1. Gene editing strategy for huIL5 mice.
Application Area
Research on asthma and eosinophilic airway diseases;
Studies on chronic rhinosinusitis with nasal polyps (CRSwNP) and hypereosinophilic syndrome;
Investigation of allergic rhinitis and atopic dermatitis;
Mechanistic studies of allergic inflammation;
Preclinical evaluation of IL-5-targeted therapeutics;
In vivo validation of immunotherapies;
Cytokine signaling pathway research.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
